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1. Introduction 
Vaccines are among the most effective public health interventions available. Global 
eradication of smallpox infection, the elimination of polio from the Western hemisphere, 
and dramatic reductions in diseases like diphtheria, tetanus, pertussis, measles, mumps, 
rubella, varicella, rotavirus, hepatitis A and B have all been achieved through immunization 
programs. The public health impact of well-structured immunization programs is well 
appreciated, but logistic and financial obstacles can interfere with vaccine availability and 
delivery. The frequency and severity of bacterial meningitis in children has also been 
favorable impacted by the widespread use of vaccines in all areas of the world where 
resources have allowed them to be implemented since the three most common causes of 
childhood meningitis, Haemophilus influenzae type B (HIB), pneumococcus, and 
meningococcus, are now, at least partially, vaccine preventable. In developed countries of 
the world, vaccines for all three of these bacterial infections are now considered the standard 
of care. Substantial progress is also being made in resource poor countries where, slowly 
and surely, the public health impact of immunization programs is being appreciated and 
international assistance to provide the money and knowledge needed for widespread 
vaccine delivery is being realized. 
Bacterial meningitis is a life threatening infection that occurs in all age groups but 
disproportionately affects infants and young children. Most cases of bacterial meningitis 
result from hematogenous seeding of the meninges during a bloodstream infection. Direct 
extension of a bacterial infection from the sinuses, middle ear, or mastoid represent other 
routes of meningeal seeding. The most common microbiologic causes of bacterial meningitis 
differ based on the age of the affected patient. Common etiologic agents of bacterial 
meningitis in the first week of life include Streptococcus agalactiae (group B Streptococcus), 
Escherichia coli, and Listeria monocytogenes. Sadly, vaccines to prevent infections caused 
by these agents have remained elusive, although some progress has been made with 
experimental vaccines against group B streptococcus. Late-onset neonatal meningitis occurs 
after the first week of life and up to three months of age and may be caused by the agents 
listed above, other enteric gram negative bacilli, Pasteurella after animal exposure, 
pneumococci, meningococci, and staphylococci.  
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During later infancy and early childhood, S. pneumoniae and N. meningitidis, account for 
80% of cases of bacterial meningitis in developed countries. Many of these infections are 
now vaccine preventable. The remaining 20% are caused by L. monocytogenes, 
Streptococcus pyogenes (group A strep) S. agalactiae (group B strep), H. influenzae (type B 
and nontypeable isolates), E. coli and other enteric gram negative rods (including 
salmonella species). Among these agents, only H. influenzae type B vaccines have been 
successful. Bacterial meningitis in adolescents and younger adults is usually caused by 
either S. pneumoniae or N. meningitides, however after the age of 50 years, L. 
monocytogenes becomes more prevalent. In elderly individuals, S. pneumoniae, N. 
meningitidis and L. monocytogenes remain the more common microbiologic etiologies, 
however a broad array of other pathogens have been described depending on the presence 
of co-morbidities, travel, and unusual exposures. 
At present, bacterial meningitis is most common in children, particularly those living in 
under-developed countries of the world. In some parts of Africa, 1 in 250 children 
developing meningitis during their first year of life (Greenwood, 1987; Scarborough et al., 
2007, Scarborough & Thwaites, 2008), and while epidemiologic surveys from the United 
States, Europe, Brazil, Israel and Canada show that bacterial meningitis is less common in 
developed parts of the world, infections are typically caused by the same bacterial species in 
all geographic areas. As noted, safe and effective vaccines have been developed to prevent 
infections caused by the three most common agents of bacterial meningitis in children—
Haemophilus influenzae type B (HIB), Streptococcus pneumoniae, and Neisseria 
meningitidis. The introduction and implementation of these vaccines have had dramatic 
effects on the incidence of bacterial meningitis in all areas of the world where they have 
been successfully introduced, but challenges remain.  
Obstacles to the prevention of bacterial meningitis in resource poor areas of the world relate 
to the cost of the vaccines, and the lack of solid infrastructure to store and deliver the 
vaccines to those most in need. A growing, and somewhat unanticipated barrier to vaccine 
coverage rates in developed countries has been a loss of public confidence in the safety of 
routine immunizations to the extent that immunization coverage rates are not as high as we 
have once achieved successfully. Even in countries where vaccine coverage remains 
excellent, cases of pneumococcal and/or meningococcal meningitis can still occur, as not all 
serotypes of these organisms are included in present day vaccines. For the most common 
causes of bacterial meningitis, vaccines are indeed available for the predominate serotypes, 
but since vaccines do not exist for every known serotype, cases will still be seen. This is 
especially important for Neisseria meningitidis serotype B, a common cause of meningitis in 
young infants. Moreover, the common etiologic agents affecting newborns (Escherichia coli 
and Streptococcus agalactiae, also commonly referred to as group B strep) and less common 
causes of bacterial meningitis in older children (Listeria monocytogenes, Staphylococcus 
aureus, Streptococcus pyogenes, and Salmonella species) are not currently preventable 
through licensed vaccines. 
2. Available licensed vaccines for the prevention of bacterial meningitis 
2.1 HIB vaccines  
Haemophilus influenzae type B is an encapsulated pleiomorphic gram negative rod that 
causes bacteremia, sepsis, pneumonia, facial cellulitis, epiglottitis, and meningitis. Before the 
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mid 1980’s, HIB caused roughly 20,000 cases of invasive disease per year in the U.S. alone. 
Almost all of these infections occurred in children under five years of age, and half of these 
infections were meningitis, making HIB the most common cause of bacterial meningitis in 
children at the time, and identifying HIB disease as a logical target for vaccine development. 
Other capsular serotypes, and non-typeable strains of H. influenzae are less common causes 
of invasive infection, but non-type B cases of meningitis are still encountered on a regular 
basis. 
2.1.1 Early HIB vaccine efforts 
In 1985, the first HIB vaccines were licensed for use in the United States for children 
beginning at age two years. The original formulations of the vaccine were pure 
polysaccharide, had an efficacy of 55-92%, and was well tolerated. Three vaccines were 
licensed—Praxis introduced b-Capsa-1, Lederle introduced Hib-imune; and Connaught 
introduced Hibvax. At the time, this was a major advance in pediatric vaccination since HIB 
was the most common cause of meningitis in children under five years of age, and carried a 
significant morbidity and mortality. Many of the infected children developed profound 
sensorineural hearing loss as a complication of developing meningitis, others suffered 
developmental and cognitive deficits, and some died. In the early days of HIB vaccine, there 
was controversy regarding the overall value of routine immunization, especially since the 
early formulations of vaccines were not effective in infants. Although it was a start, the 
strategy that employed the use of pure polysaccharide vaccines was suboptimal for the 
prevention of invasive HIB infection for several additional reasons. First, polysaccharide 
vaccines are not immunogenic in patients under two years of age, the age group at highest 
risk for HIB disease. Second, polysaccharide immunogens are processed by the immune 
system in a T-cell independent manner. In the absence of T-cell engagement, immunity 
cannot be effectively boosted with subsequent doses of vaccine. B cells are certainly 
stimulated to produce antibodies, but the effect is relatively short lived, and antibody titers 
wane over the period of several years. An absence of T-cell help impairs the durability of the 
immune response. Five years following receipt of a polysaccharide vaccine, the humoral 
evidence of prior vaccination (and immunity), is reduced or no longer detected. Third, serial 
re-administration of polysaccharide vaccines to individuals at any age, particularly if done 
so at closely spaced intervals, leads to lower antibody titers than the first dose. This 
phenomenon, known as ‘hypo-responsiveness’ remains a major limitation for the use of any 
pure polysaccharide vaccine.  
2.1.2 Solving the problems of polysaccharides vaccines 
Clinical vaccine research suggested early on that the limitations associated with the use of 
polysaccharide immunogens could be overcome through the use of an elegant biochemical 
trick. The same polysaccharide antigens used in the original HIB vaccines were covalently 
linked to a simple peptide. Peptides that have been used successfully in this manner include 
tetanus and diphtheria toxoids, the outer membrane protein of Neisseria menigitidis, and 
CRM197 (cross reacting material 197, a protein similar to naturally occurring diphtheria 
toxin). The presence of such a peptide altered the manner in which the immune system 
processed the antigen, specifically with regard to T-cell engagement, and allowed the 
vaccine to induce a robust immune response in children as young as six weeks of age. Serial 
doses provide additional protection and higher antibody concentrations, and booster doses 
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show clear evidence of immune memory. The technique whereby polysaccharide antigens 
are biochemically linked to a peptide produces a ‘conjugate’ vaccine. Table 1 shows examples 
of polysaccharide and conjugate vaccines made by different manufacturers, the conjugate 
protein used to develop them, and the year each was introduced in the United States. The 
successful development of conjugate HIB vaccines paved the way for the development of 
several other conjugate vaccines, including those currently in use for the prevention of both 
pneumococcal and meningococcal infections. Early pure polysaccharide, and later generation 
conjugate vaccines for all three types of infection are included in the Table. 
Vaccine Trade name Manufacturer Immunogens 
Conjugate 
protein 
Introduced 
in the U.S. 
HIB 
B-Caspa-1 
Hib-Imune 
Hibvax 
Praxis 
Lederle 
Connaught 
PRP 
PRP 
PRP 
None 
1985, no 
longer used 
 HIBTITER Wyeth HbOC CRM197 
1990, no 
longer used 
 PedvaxHIB Merck PRP 
OMP N. 
meningitidis 
1989 
 ActHIB Sanofi Pasteur PRP 
Tetanus 
toxoid 
1993 
 OmniHIB GlaxoSmithKline PRP 
Tetanus 
toxoid 
1993, no 
longer used 
 ProHIBIT Connaught PRP 
Diphtheria 
toxoid 
1987, no 
longer used 
 Hiberix GlaxoSmithKline PRP 
Tetanus 
toxoid 
2010 
Pneumococcal Pneumovax Merck 14 valent None 
1977, no 
longer used 
 
Pneumovax 
23 
Merck 23 valent* None 1983 
 Prevnar Pfizer 
4, 6B, 9V, 14, 
18C, 19F, 23F 
CRM197 2000 
 Prevnar 13 Pfizer 
1, 3, 4, 5, 6A, 
6B, 7F, 9V, 14, 
18C, 19A, 19F, 
23F 
CRM 197 2010 
Memingococcal Menomune Sanofi Pasteur A, C, Y, W135 None 1981 
 Menactra Sanofi Pasteur A, C, Y, W135 
Diphtheria 
toxoid 
2005 
 Menveo Novartis A, C, Y, W135 CRM197 2010 
*1, 2, 3, 4, 5, 6B , 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F 
Abbreviations: PRP (polyribosylribitol phosphate), CRM (cross reacting material), OMP (outer 
membrane protein), HbOC (Haemophilus B oligosaccharide conjugate) 
Table 1. Vaccines to Prevent HIB, Pneumococcal and Meningococcal Infections in the United 
States 
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With the introduction of conjugate HIB vaccine during the late 1980s throughout the U.S. 
and other developed countries, rates of all cause bacterial meningitis fell dramatically along 
with the observation that the mean age at presentation from any cause of bacterial 
meningitis went from 15 mos in 1986 to 25 years in 1995 (Schuchat et al., 1997; Berg et al., 
1996; Giorgi Rossi et al., 2009; Mishal et al., 2008; Theodoridou et al., 2007; Urwin et al., 1994; 
Weiss et al., 2001; Schlech et al., 1985 Wenger et al., 1990). This age shift was a direct effect of 
near complete elimination of HIB meningitis in the under five-year old age group. This is 
perhaps the most notable recent, and publically under-recognized vaccine success story of 
recent years. Once a cause of approximately 10,000 cases of bacterial meningitis in children 
every year in the U.S. alone, there is currently an average of fewer than 100 cases of invasive 
HIB disease reported annually.  
HIB vaccine programs are among the most effective modern public health interventions of 
the 20th century. Pediatric cases seen in the U.S. in the present day are almost always 
described in unvaccinated, under-vaccinated, or immune deficient patients. When invasive 
HIB disease is discovered in a vaccinated child, testing should always be performed to 
determine if that child has an immune deficiency. The HIB success story is mirrored across 
the globe in areas where resources have permitted widespread introduction of vaccine to 
children. These results are clear and impressive. In every area of the world where vaccine 
programs are initiated, HIB disease, including HIB meningitis, virtually disappears.  
The public health benefits of HIB vaccination have not been realized in all corners of the 
globe, however. Delivery of HIB and other vaccines to resource challenged areas of the 
world remains suboptimal. Globally, it is estimated that about 38% of infants have HIB 
vaccine available to them, but progress in improving this percentage is steady. Even 38% of 
the worlds’ children translates to roughly 130,000 lives saved annually from pneumonia and 
meningitis caused by HIB. In the last decade alone, combined efforts on the part of the 
World Health Organization, UNICEF, the Bill and Melinda Gates Foundation, and other 
international agencies have led to more vaccine availability in the areas of the world that 
still need it the most. In 1997, 29 countries were using conjugate HIB vaccine, but by 2009, 
161 countries had introduced it. To date, 29 countries are still without access to HIB vaccine 
for infants, and the epidemiology of HIB infection in those areas remains similar to the 
problem seen in the U.S. prior to 1985. While there has been progress in Africa and some 
parts of Asia, significant effort, education, and resources are still needed in the 
underdeveloped world to prevent this form of meningitis. 
2.2 Pneumococcal vaccines 
Streptococcus pneumoniae are encapsulated gram positive diplococci that continue to cause 
invasive infections at all ages. Of the 92 different pneumococcal serotypes (grouped into 46 
serogroups based on immunologic similarities) that have been identified based on antigenic 
differences in their capsular polysaccharides, ten serogroups account for most of the 
pediatric invasive pneumococcal infections worldwide with serogroups 1, 3, 6, 14, 19 and 23 
being the most common. Pneumococci commonly infect the sinopulmonary tract causing 
otitis media, sinusitis, and pneumonia. Bacteremia with sepsis is not uncommon. Meningeal 
seeding, with a resulting bacterial meningitis can occur at any age, including previously 
healthy individuals, and patients with defined risk factors, including immune deficiency, 
HIV infection, asplenia, hemoglobinopathies, diabetes and alcoholism. Worldwide, S. 
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pneumoniae remains the most common cause of bacterial meningitis identifying it as an 
important target for vaccine development. 
2.2.1 Early vaccine development 
Vaccines designed to prevent invasive pneumococcal disease were available in the early 
1900s, but early goals were focused primarily in the prevention of lower respiratory tract 
infection in adults. Two hexavalent vaccines were licensed for use in adults after World War 
II, but with the emerging availability of antibiotics, enthusiasm for the use of vaccines to 
prevent disease waned. In the absence of public demand, the vaccines were removed from 
the market. Interest in the prevention of pneumococcal infections re-emerged in the 1960s. A 
14-valent pure polysaccharide vaccine was licensed for use in adults in 1977, ultimately 
being replaced by a new generation polysaccharide 23-valent vaccine in 1983. The 23-valent 
polysaccharide vaccine, which is still available, was FDA licensed in the United States in 
1983 for use in adults and high-risk children older than 2 years. Its role has been primarily to 
prevent pneumococcal pneumonia in high-risk adults. Its major limitation as a pure 
polysaccharide vaccine (it is not a conjugate vaccine) is that it is poorly immunogenic in 
young children. Like other polysaccharide vaccines, it is processed by the immune system in 
a T-cell independent manner so the duration of immune protection is brief, and there is no 
potential for boosting with subsequent doses.  
In 2000, a heptavalent pneumococcal vaccine, Prevnar, was added to the universal pediatric 
immunization schedule in the U.S. resulting in an almost immediate reduction in invasive 
pneumococcal infections, including a reduction in cases of meningitis. U.S. population-
based data from the Active Bacterial Core Surveillance was published in 2003 showing a 
59% decline in pneumococcal meningitis in young children (Whitney et al., 2003), and 
Nationwide Inpatient Service data showed that the incidence rate fell by 33% in children less 
than 5 years of age (from 0.8 to 0.55 cases per 100,000 population) (Tsai et al., 2008).  
The power of national surveillance, coupled with the impressive efficacy of pneumococcal 
vaccine illustrated the public health benefits in just three years following vaccine 
introduction. When it is appreciated that Prevnar was in somewhat short supply during 
much of those early years, the dramatic beneficial effect becomes even more obvious. The 
majority of children in the U.S. during 2000-2002 received a 3-dose primary vaccine series, 
but an Advisory Committee on Immunization Practices recommendation to defer the 
booster fourth dose until supplies were available led to substantial delays in the timeliness 
of completing the four dose series. Despite this difficulty with timeliness to vaccine series 
completion, the public health impact of conjugate vaccine was almost immediately 
recognized through surveillance networks. 
The heptavalent (7-valent) pneumococcal vaccine Prevnar included conjugated 
pneumococcal polysaccharide antigens against serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. At 
the time of licensure, these capsular types were the most likely to cause invasive infection in 
children in the Unites States. Serotype prevalence varies somewhat according to world 
geography, but for the most part, the same types are responsible for invasive infection in 
most of the world. As conjugate pneumococcal vaccine was being developed, another public 
health problem related to infections caused by S. pneumoniae had already become well 
recognized. Strains of S. pneumoniae had gradually emerged that were less and less 
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susceptible to penicillin. Treatment of pneumococcal infections with penicillin or other beta-
lactam antibiotics was no longer ‘guaranteed’ to eradicate infection. This problem impacted 
empiric management of mild to moderate infections such as otitis media and pneumonia, 
but also raised serious concerns about how to best manage empiric antibiotics in serious and 
life-threatening infections such as meningitis.  
As antibiotic resistance increased in pneumococci, moderate and severe infections began to 
be managed with different antimicrobial regimens. Penicillin treatment of severe disease 
was used only after antimicrobial susceptibility profiles were confirmed. The problem was 
not isolated to the use of penicillin, as the mechanism of penicillin resistance in S. 
pneumoniae depends on a series of mutations in its penicillin binding proteins (PBPs) that 
also alter the antimicrobial susceptibility to all beta lactam antibiotics. It should be 
understood that this mechanism of antibiotic resistance does not depend on the production 
of a beta-lactamase enzyme, and that beta lactamase producing S. pneumoniae isolates have 
not ever been described. Instead, antibiotic pressure has led some strains of S. pneumoniae 
to alter their PBPs so that their affinity for penicillin is reduced. When this occurs, the 
penicillin can no longer bind to and inhibit the transpeptidase activity of the PBP, a function 
that is necessary for peptidoglycan cross linking. This biochemical alteration becomes 
obvious in the laboratory as gradual increases in the minimal inhibitory concentrations 
(MICs) of penicillin, and ultimately in the observation that the organism is ‘intermediate’ or 
‘resistant’ to penicillin. As penicillin resistant strains gain additional mutations in these 
PBPs, the MICs to all beta lactam antibiotics begin to increase. MICs to first, then second, 
and then to third generation cephalosporins increase. Pneumococci that are resistant to 
advanced generation cephalosporins like cefotaxime and ceftriaxone are now encountered 
on a regular basis. The emergence of these resistant strains has led to a change in how 
bacterial meningitis is treated empirically, where a third generation cephalosporin 
(ceftriaxone or cefotaxime) in combination with vancomycin is typically used until 
antimicrobial susceptibility profiles are known. The rationale for incorporating vancomycin 
into the empiric regimen is to be sure that every patient with pneumococcal meningitis has 
effective antimicrobial therapy initiated at the time that meningitis is suspected. When the 
microbiology laboratory confirms that the infection is caused by S. pneumoniae, and that the 
infecting organism is susceptible to penicillin or a third generation cephalosporin, the 
treatment can be ‘de-escalated’ to the appropriate antibiotic.  
One of the under-appreciated benefits of introducing the conjugate pneumococcal vaccine in 
the U.S. in 2000 was the observation that the original seven conjugate vaccine serotypes 4, 
6B, 9V, 14, 18C, 19F, and 23F were among the most likely to be penicillin resistant. This 
offered the potential to reduce infection caused by the most prevalent pneumococci, while at 
the same time reduce the possibility that infections would be caused by antibiotic resistant 
strains. During the decade following introduction of the 7-valent conjugate vaccine, there 
was a substantial reduction in invasive pneumococcal infections reported in children, 
including meningitis, but a troubling pattern began to emerge in the form of nonvaccine 
replacement serotypes. Like early prevalent pneumococcal serotypes, several of these 
replacement types were resistant to beta lactam antibiotics. 
In 2010, the heptavalent pneumococcal vaccine was replaced with a newly developed 13-
valent vaccine (by the same manufacturer) to expand the number of covered serotypes. The 
new generation 13-valent vaccine became available in 2010, and was immediately 
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recommended as a replacement for the 7-valent vaccine. The additional serotypes included 
1, 3, 5, 6A, 7F, and 19A. The inclusion of serotypes 6A and 19A are of particular importance 
in this new generation vaccine as these capsular types were the ones that emerged as the 
most serious replacement serotypes during the successful decade following introduction of 
the heptavalent vaccine. Serotype 19A remains a serious threat. Some infections caused by 
this strain are highly resistant to all penicillins, cephalosporins, and carbapenems making 
treatment for infections of the central nervous system challenging. In such situations, 
treatment with vancomycin and/or lineazolid has been successful. As experience with and 
implementation of the 13 valent conjugate vaccine continues, an optimistic possibility is that 
infections caused by the most difficult-to-treat pneumococcal strains will diminish. The 
possibility that new serotypes could emerge as novel replacement serotypes remains a 
threat, highlighting the need for ongoing surveillance. 
Like HIB vaccines, conjugate pneumococcal vaccines are not available in all parts of the world. 
In the developing world, invasive pneumococcal disease remains the 5th leading cause of 
childhood mortality with an estimated one million deaths annually in children under five 
years of age. It is the single most common cause of bacterial meningitis beyond the newborn 
period in all age groups. By the end of 2009, 44 countries worldwide had introduced conjugate 
pneumococcal vaccine representing approximately 11% of the global birth cohort.  
The prevention of invasive pneumococcal infection in developing areas of the world has 
been identified as a priority of the Bill and Melinda Gates Foundation. Working with the 
Global Alliance for Vaccines and Immunizations (GAVI), a collaborative effort between the 
World Health Organization (WHO), UNICEF, the U.S. Center for Disease Control and 
Prevention, and the World Bank, the Bill and Melinda Gates Foundation and other civil 
organizations have initiated a long term strategy to bring conjugate pneumococcal vaccine 
to eligible countries. Through the efforts and resources of GAVI, conjugate pneumococcal 
13-valent vaccines have recently been introduced in Kenya, Sierra Leone, Yemen, Guyana, 
Honduras and Nicaragua. A dozen more countries will be included in the effort by the end 
of 2011, and 40 GAVI eligible countries will have infant and childhood pneumococcal 
vaccination programs by the end of 2015. Data to track the impact of such vaccine programs 
on childhood morbidity and mortality will be collected and shared with all stakeholders to 
ensure that the programs develop sustainability over time. Reminiscent of programs such as 
the polio vaccination partnership with the March of Dimes in the 1940s, this ambitious 
initiative will save lives and bring education regarding the value of immunizations to areas 
of the world that need them most.  
2.3 Meningococcal vaccines 
N. meningitidis is a gram-negative diplococcus that is commonly carried in the human 
nasopharynx. The specific risk factors that lead to invasive disease are incompletely defined. 
When an individual acquires the organism from another person, the most common outcome 
is colonization for a period of time. Some individuals can carry N. meningitidis in their 
upper respiratory tract for prolonged periods of time. Presumably, such individuals develop 
mucosal immune responses, including secretory immunoglobulin A that prevents  
invasion. Specific risk factors for the development of invasive disease include new 
acquisition of a new serotype, recent or current upper respiratory tract infection, smoking, 
alcohol consumption, and age.  
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When N. meningitidis invades, it enters the bloodstream, causing septicemia. 
Meningococcemia is classically associated with a petechial rash that rapidly progresses to 
purpura. It the most violent form of infection, referred to as purpura fulminans, death can 
ensue within a few hours. Bacteria seed the meninges in approximately half of all cases. Less 
commonly, patients develop lobar pneumonia, epiglottitis, septic arthritis, or purulent 
pericarditis. Meningitis accounts for nearly half of all invasive meningococcal infections; 
more than half of survivors have long-term complications including cognitive defects, 
cranial nerve palsies, and sensorineural hearing loss.  
The 12 serogroups of N. meningitidis known to infect humans are characterized by the 
polysaccharide expressed on their capsule: A, B, C, 29-E, H, I, K, L, W-135, X, Y and Z. 
Clinically, the most relevant, and most prevalent types are A, B, C, W135, and Y. While 
uncommon, outbreaks caused by other capsular types have been described. Nasopharyngeal 
carriage of the bacterium is relatively common. In the U.S., carrier prevalence in the general 
population is approximately 10%. During the teen years, carriage has been described to be 
as high as 35%, and in environments of close contact such as military barracks and college 
residence halls, carriage rates may approach 100% (vanDeuren et al., 2000). The balance 
between carriage and the development of infection is influenced by both host and 
environmental factors (Caugant et al., 2007; Dull et al., 2001). Social factors also increase risk, 
such as intimate contact with an infected person, or living or working under crowded 
conditions, smoking, and alcohol consumption (MacLennan et al., 2006; Imrey et al. 1995).  
The proportion of cases of meningococcal disease caused by individual serogroups A, B, C, 
W-135, and Y vary by geographic region. In developed countries, serogroup distribution 
also differs within regions. In Great Britain, for example, serogroups B and C account for 
over 90% of cases, while in New Zealand, serogroup B alone causes 87% of all cases. In 
contrast, meningococcal meningitis diagnosed in the African “meningitis belt,” is usually 
caused by serogroup A. Attack rates during epidemics in Africa approach 1% of the 
population (Pinner et al., Moore P.s., 1992; Moore et al., 1989). In Saudi Arabia, where 
serogroup W-135 predominates, attack rates have been described at 25 per 100,000 
population during the Hajj (Rosenstein et al., 2001; Pollard AJ, 2004; Wilder-Smith et al., 
2003; Wilder-Smith et al., 2003). The country of Niger has recently experienced the 
emergence of serogroup X where it caused half of 1,139 cases in 2006 (Boisier et al., 20007). 
In the U.S. between 1200 and 3500 cases of meningococcal disease occur annually  
(0.9 to 1.5 cases per 100,000 population). Data for 2006 through 2008 show that serogroups B, 
Y and C account for most of the U.S. cases (http://www.cdc.gov/abcs/reports-
findings/survreports/mening09.html). Unlike the African ‘meningitis belt’, and areas of 
Asia where meningococcus type A infections are endemic, disease caused by serogroup A 
has not been detected in the U.S. since the late 1970s. Serotyping of 843 strains isolated 
between 1964 and 1967 demonstrated that serogroup A accounted for 1.3% of infections 
during that time period (Evans et al., 1968). An outbreak among skid row occupants 
occurred between 1975 and 1977 (Centers for Disease Control and Prevention 2009). Since 
that time, there has been a shift in serogroup predominance. Based on serotyping of 261 
isolates from patients with meningococcal disease between 1989 and 1991, serogroups B and 
C accounted for more than 90% of cases. Furthermore, between 1998 and 2000, the 
proportion of serogroup Y cases increased from 2% to 33% of the total. Data for 2006 
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through 2008 show that serogroups Y (33%) and C (29%) continue to account for a large 
proportion of U.S. cases.  
Given the fulminant nature of the infection, with an overall mortality rate of ~10%, 
prevention has become a priority. Vaccines for the prevention of invasive meningococcal 
infection were first available in the United States in 1971, but for more than two decades 
targeted only higher risk individuals. The first available vaccine, a polysaccharide capsular 
type C vaccine, was used almost exclusively in military recruits to control outbreaks that 
were being seen in military barracks. The high attack rate of meningococcal infection in this 
cohort of individuals is not surprising. Otherwise young, healthy individuals from different 
geographical areas of the country, where different N. meningitidis serotypes are prevalent, 
are brought together in close proximity under stressful conditions. Acquisition of a new 
serotype is common under such condition, and invasive disease more likely during 
physiologic stress and other behavioral risk factors.  
A quadrivalent, non-conjugated pure polysaccharide meningococcal vaccine containing 
serotypes A, C, Y and W135 (Menomune) became available for use in the U.S. in 1981, and 
was primarily used to protect military recruits, travelers going to endemic areas and 
immunocompromised individuals. By 1999, the U.S. Centers for Disease Control and 
Prevention (CDC) and American College Health Association (ACHA) recommended the 
vaccine for all incoming college freshmen given the increased risk of invasive disease 
described in this population. As with other pure polysaccharide vaccines, protective 
immunity is short-lived, but given the brief period of increased risk in college freshman and 
in military recruits, the vaccine was widely used. As with pure polysaccharide HIB and 
pneumococcal vaccines, lack of T-cell engagement leads to inability to boost prior responses. 
Similarly, no change in nasopharyngeal carriage was expected. Subsequent vaccine 
development allowed for emerging conjugate vaccines, and led to changes in how these 
vaccines are used currently.  
Globally, the first large scale experience with conjugate meningococcal vaccines occurred in 
the 1990s. One of the best examples comes from the United Kingdom where an epidemic of 
group C meningoccocal infection was causing a serious public health problem. The epidemic 
peaked in 1999 with an estimated 1500 cases and 150 deaths in that country alone. In 
November 1999, the public health ministry introduced a monovalent group C meningococcal 
vaccine as a public health measure, focusing first on vaccinating teenagers. Population based 
surveillance was used to monitor the incidence of disease as the vaccination program was 
introduced. Within 12 months of vaccine delivery through public health efforts, a marked 
decline in the incidence of disease was observed, and the vaccine program was expanded to 
young children. Vaccine effectiveness was estimated to be 90% for vaccinated individuals, but 
a broader scale benefit was noted for the overall population, argued to be secondary to a 
reduction in nasopharyngeal carriage of the organism leading to reductions in disease 
transmission among the unvaccinated population as well. The observation that conjugate 
vaccines lead to reductions in nasopharyngeal carriage and provide a community immunity 
benefit that extends to those who are not vaccinated is unique to conjugate vaccines as pure 
polysaccharide formulations do not afford this benefit. In addition to the monovalent 
conjugate group C vaccine used to control the U.K. epidemic, several other mono and bivalent 
conjugate vaccines are currently available in the global market.  
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The first conjugate meningococcal vaccine (which includes immunogens targeting the 
same four serotypes in the polysaccharide vaccine Menomune-- A, C, Y and W135) 
became available in the U.S. in 2005, it was immediately recommended that it replace 
polysaccharide vaccine for most individuals. Since clinical vaccine trials demonstrated 
safety and efficacy up to age 55, but not beyond, the polysaccharide vaccine is still 
officially recommended for individuals 55 years and older. Conjugate meningococcal 
vaccines are recommended for use in high risk individuals including those with terminal 
complement deficiency, asplenia, HIV infection, and in those who travel to areas of the 
world endemic for meningococcal infection. In addition, given the epidemiology of 
invasive meningococcal infection during adolescence, conjugate meningococcal vaccine 
was added to the universal immunization schedule starting at 11-12 years of age in 2005. 
Because of concerns that vaccine effectiveness may drift over time, the U.S. Advisory 
Committee on Immunization Practices added a second dose recommendation at age 16 
years (up to age 21) as a booster. 
Recent clinical trials have also evaluated the conjugate vaccines for safety and efficacy in 
younger children, and by 2011, vaccine became available for use as early as 9 mos of age for 
high-risk individuals and travelers (Menactra). A combination HIB-Meningococcal C/Y 
vaccine that was studied in clinical trials in the U.S. is currently under review for licensure 
by the Food and Drug Administration. In the U.S., the ACIP has been reluctant to 
recommend universal use of meningococcal conjugate vaccines under the age of 11 years, 
since more than half of infant infections are currently caused by the non-vaccine serotype B 
meningococcus. Meningococcal vaccines designed to protect individuals against serogroup 
B illness are in phase 3 clinical vaccine efficacy trials. 
2.3.1 Meningococcus serotype B and the unique challenges it presents 
Given the epidemiology of invasive meningococcal disease, including a substantial 
contribution from N. meningitidis type B should not be capitalized, it is logical to question 
why it has been so difficult to develop a serotype B vaccine. The native group B 
polysaccharide is a poor vaccine candidate because it contains epitopes that cross-react with 
sialylated proteins in human brain. New strategies have emerged to use alternative 
components of the group B meningococcus as vaccine antigens since such residues have 
been identified that are not cross reacting with the same human tissues. Ultimately, the 
development of a safe and effective B vaccine will likely capitalize on these non-cross 
reacting group B antigens from genetically modified strains. Several such vaccine candidates 
are already undergoing clinical trials.  
Reported cases of meningococcal meningitis in the U.S. are currently at historically low 
rates. It is premature to credit the introduction and implementation of conjugate 
meningococcal vaccines for this epidemiologic observation, but in the coming years it will 
become clear whether this promising trend continues. The obvious decline in both HIB and 
pneumococcal meningitis following the introduction of vaccines for those infections is 
already compelling. Vaccine programs are highly effective. A summary of the current 
Advisory Committee on Immunization Practices for use of HIB, pneumococcal and 
meningococcal vaccines in summarized in Table 2. 
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Vaccine 
Age Given Recommendation High Risk 
Conditions  
HIB conjugate 
2, 4, 6, 12-15 
mos* 
Universal 
Universal 
Pneumococcal 
polysaccharide 
After 23 mos Following conjugate 
series, 2 doses 5 yrs 
apart 
Sickle cell disease, 
asplenia, inherited 
or acquired immune 
deficiency, chronic 
cardiac and/or 
pulmonary disease, 
CSF leaks, renal 
insufficiency, 
diabetes 
Pneumococcal 
conjugate 
2, 4, 6, 12-15 mos Universal 
Universal 
Meningococcal 
polysaccharide 
56 yrs and older High risk See risk factors in 
conjugate box below. 
Meningococcal 
conjugate vaccine 
not approved for use 
after age 55 yrs. 
Meningococcal 
conjugate 
11-21 yrs 
 
9 mos-55 yrs 
Universal 
 
High Risk 
Universal 
 
Terminal 
complement or 
properdin 
deficiency, asplenia, 
military recruits, 
college freshman 
living in catered 
halls, HIV infection, 
travel to endemic 
areas of the world 
 *6 mos dose not needed if PedvaxHIB is used 
Table 2. Summary of recommendations from the Advisory Committee on Immunization 
Practices (ACIP) of the United States for the use of HIB, pneumococcal and meningococcal 
vaccines 
3. References  
Berg S, Trollfors B, Claesson BA, Alestig K, Gothefors L, Hugosson S, Lindquist L, Olcen P, 
Romanus V, Strangert K. Incidence and prognosis of meningitis due to 
Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitides in 
Sweden. Scand J Infect Dis. 1996;28:247-252. 
www.intechopen.com
 
Vaccines to Prevent Bacterial Meningitis in Children 
 
63 
Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, Mainassara HB, Tenebray B, Kairo KK, 
Giorgini D, Chanteau S. Meningococcal meningitis:unprecedented incidence of 
serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007;44:657-663. 
Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal carriage studies.  FEMS 
Microbiol Rev. 2007;31(1):52-63. 
Centers for Disease Control and Prevention. Notifiable diseases/deaths in selected cities 
weekly information. MMWR. 2009;58(16):440-451. 
Dull PM, Abdelwahab J, Sacchi CT, et al. Neisseria menigitidis serogroup W-135 carriage 
among US travelers to the Hajj. J Infect Dis. 2005;191:33-39. 
Evans JR, Artenstein MS, Hunter DH. Prevalence of meningococcal serogroup and 
description of 3 new groups. Am J Epidemiol. 1968;87:643-646. 
Filice GA, Englender SJ, Jacobson JA, et al. Group A meningococcal disease in skid rows: 
epidemiology and implications for control Am J Public Health. 1984;74:253-254. 
Giorgi Rossi P, Mantovani J, Ferroni E, Forcina A, Stranghellini E, Curtale F, Borgia P. 
Incidence of bacterial meningitis (2001-2005) in Lazio, Italy: the results of an 
intergrated surveillance system. BMC Infect. 2009;9:13. 
Greenwood BM. 1987. The epidemiology of acute bacterial meningitis in tropical Africa, 
p.93-113. In JD Williams and J Burnie (ed), Bacterial meningitis. Academic Press, 
London, UK. 
Imrey PB, Jackson LA, Ludwinski PH, et al. Meningococcal carriage, alcohol consumption, 
and campus bar patronage in a serogroup C meningococcal disease outbreak. J Clin 
Microbiol. 1995;33:3133-3137. 
MacLennan J, Kafatos G, Neal K, et al. Social behavior and meningococcal carriage in British 
teenagers. Emerg Infect Dis. 2006;12:950-957. 
Mishal J, Embon A, Darawshe A, Kidon M, Magen E. Community acquired acute bacterial 
meningitis in children and adults: an 11 year survey in a community hospital in 
Israel. Eur J Intern Med. 2008;19:421-426. 
Moore PS, Reeves MW, Schwartz B, Gellin BG, Broome CV. Intercontinental spread of an 
epidemic group A Neisseria meningitides strain. 1989 Lancet ii:260-263. 
Moore PS. Meningococcal meningitis in sub-Saharan Africa: a model for the epidemic 
process. Clin Infect Dis 1992;14:515-525. 
Pinner RW, Gellin BG, Bibb WF, Baker CN, Weaver R, Hunter SB, Waterman SH, Mocca LF, 
Frasch CE, Broome CV. Meningococcal disease in the UNited States- 1986. 
Meningococcal Disease Study Group. J Infect Dis 1991;164:368-374. 
Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr 
Infect Dis J. 2004;23(12 suppl):S274-S279. 
Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med. 
2001;344:1378-1388. 
Scarborough M, Gordon SB, Whitty CJ, French N, Njalale Y, Chitani A, Peto TE, Lalloo DG, 
Zijlstra EE. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. 
N Engl J Med 2007;357:2441-2450. 
Scarborough M, Thwaites GE. The diagnosis and management of acute bacterial meningitis 
in resource-poor settings. Lancet Neurol 2008;7:637-648. 
Schlech WF, Ward JI, Band JD, Hightower A, Fraser DW, Broome CV. Bacterial meningitis in 
the UNited States, 1978 through 1981. The national bacterial meningitis surveillance 
study. JAMA 1985;253:1749-1754. 
www.intechopen.com
 
Meningitis 
 
64
Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL, Lefkowitz L, 
Perkins BA. Bacterial meningitis in the United States in 1995. Active surveillance 
team. N Engl J Med 1997;337:970-976. 
Theodoridou MN, Vasilopoulou VA, Atsali EE, PAngalis AM, Mostrou GJ, Syriopoulou VP, 
Hadjichristodoulou. Meningitis registry of hospitalized cases in children: 
epidemiological patterns of acute bacterial meningitis throughout a 32-year period. 
BMC Infect Dis 2007;7:101. 
Tsai CJ, Griffen MR, Nuorti JP, Grijalva CG. Changinf epidemiology of pneumococcal 
meningitis after the introduction of pneumococcal conjgate vaccine in the United 
States. Clin Infect Dis. 2008;46:1664-1672. 
Urwin G, Yuan MF, Feldman RA. Prospective study of bacterial meningitis in North East 
Thames region, 1991-3, during introduction of Haemophilus influenzae vaccine. 
BMJ 1994;308:1412-1414. 
van Deuren M, Brandtzaeg P, van der Meer JW. Update on meningococcal disease with 
emphasis on pathogenesis and clinical management. Clin Microbiol Rev. 
2000;13:144-166. 
Weiss DP, Coplan P, Guess H. Epidemiology of bacterial meningitis among children in 
Brazil, 1997-1998. Rev Saude Publica 2001;35:249-255. 
Wenger JD, Hightower AW, Facklam RR, Gaventa S, Broome CV. Bacterial meningitis in the 
Unites States, 1986: report of a multi-state surveillance study. The bacterial 
meningitis study group. J Infect Dis 1990;162:1316-1323. 
Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, 
Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A. Decline 
in invasive pneumococcal disease after the introduction of protein-polysaccharide 
conjugate vaccine. N Engl J Med 2003;348:1737-1746. 
Wilder-Smith A, Barkham TMS, Ravindran S, et al. Persistence of W135 Neisseria meningitidis 
Carriage in Returning Hajj Pilgrims: Risk for Early and Late Transmission to 
Household Contacts. Emerg Infect Dis. 2003;9:123-126. 
Wilder-Smith A, Goh KT, Barkham T, Patoon NI. Hajj-associated outbreak strain of 
Neisseria meningitides serogroup W135: estimates of the attack rate in a defined 
population and the risk of invasive disease developing in carriers. Cin Infect Dis 
2003;36:679-683.  
http://www.cdc.gov/abcs/reports-findings/survreports/mening09.html 
Accessed March 6, 2011 
www.intechopen.com
Meningitis
Edited by Prof. George Wireko-Brobby
ISBN 978-953-51-0383-7
Hard cover, 232 pages
Publisher InTech
Published online 30, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Meningitis is a medical emergency requiring a rapid diagnosis and an immediate transfer to an institution
supplied with appropriate antibiotic and supportive measures. This book aims to provide general practitioners,
paediatricians, and specialist physicians with an essential text written in an accessible language, and also to
highlight the differences in pathogenesis and causative agents of meningitis in the developed and the
developing world.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Joseph Domachowske (2012). Vaccines to Prevent Bacterial Meningitis in Children, Meningitis, Prof. George
Wireko-Brobby (Ed.), ISBN: 978-953-51-0383-7, InTech, Available from:
http://www.intechopen.com/books/meningitis/vaccines-to-prevent-bacterial-meningitis-in-children
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
